Japanese pharmaceutical company Astellas Pharma Inc. (TYO: 4503) has inaugurated a state-of-the-art laboratory and office facility in the United States, marking a significant step in the company’s commitment to research and development. The new 14,307 sq.m. site represents an investment of USD 90 million and will serve as a hub for a variety of business units, including Gene Therapies, Xyphos Biosciences, Business Development, and the Rx+ Business Accelerator.
This strategic expansion is expected to bolster Astellas’ research capabilities, technical expertise, and medical development operations, while also enhancing its commercial presence in the US market. By consolidating these key business units under one roof, the company aims to foster innovation, streamline operations, and accelerate the development of novel therapies.- Flcube.com
